Vivos Stock Price, News & Analysis

Vivos Inc. (OTCQB: RDGL) has announced a partnership with the Johns Hopkins Veterinary Clinical Trials Network for the Isopet® initiative, aimed at conducting animal studies on specific cancers. This collaboration is expected to enhance data collection for publishing in leading journals, thereby increasing awareness and acceptance of Isopet® within the veterinary oncology community. The Isopet® technology, based on yttrium-90, targets tumor treatment in animals and parallels the human treatment method, Radiogel™. The company aims to expand its regional centers and establish a robust presence in the veterinary market.

Vivos Inc. (OTCQB: RDGL) has announced that Johns Hopkins University is now an Isopet® regional clinic, which will conduct new studies on various cancers. This collaboration aims to generate high-quality data for publication, enhancing awareness within the veterinary oncology community. The Isopet® device, based on Yttrium-90, is designed to treat animal tumors effectively and can drive revenue through sales to veterinary hospitals and clinics. The FDA confirmed Isopet® as a medical device in 2018, streamlining its market introduction.

Vivos Inc. (OTCQB: RDGL) has signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East Meadow, New York, to establish an IsoPet regional therapy center. This center will focus on treating cancerous tumor margins post-surgery, potentially extending pet lives. Following the acquisition of a radioactive material handling license and necessary training, the center aims to expand its capabilities to treat other solid tumors. The initiative is backed by the Veterinary Medicine Advisory Board, led by Dr. Mike Korenko.

Vivos Inc. (OTCQB: RDGL) has successfully developed nine certification training modules in collaboration with FX Masse, aimed at establishing regional clinics for IsoPet therapy. These modules, now available on the FX Masse website, facilitate a flexible learning environment for new clinics before hands-on training. The training process will be linked to handling licenses for radioactive materials. With the usage of innovative hydrogel technology, Vivos Inc. delivers targeted radiation therapy for tumors in both animals and humans, enhancing treatment safety and efficacy.

Vivos Inc. (OTCQB: RDGL) announced the submission of its Investigational Device Exemption (IDE) for the Early Feasibility Medical Device Study of Y-90 RadioGel™ to the FDA. This marks a significant milestone, encouraging enhanced communication and an efficient review process. The IDE includes the Mayo Clinic's Clinical Trial Protocol. Dr. Mike Korenko noted FDA support for the project. RadioGel™ aims to treat tumors using localized radiation, reducing side effects associated with traditional therapies. This IDE submission signals Vivos's progress in cancer treatment innovation.

Vivos Inc. (OTCQB: RDGL) has successfully completed its first IsoPet® therapy on a horse with a tumor at the University of Missouri. This marks an expansion of IsoPet® into the equine market, providing a unique treatment option for larger animals. The horse's tumor has already stopped growing post-treatment. Dr. Mike Korenko emphasized the importance of this development for the company's business strategy, aiming to further refine the technique and collaborate with a private clinic. Interested horse owners can now express their interest in the therapy via the company’s website.

Vivos Inc. (OTCQB: RDGL) has successfully extended its IsoPet® trademark protection internationally, confirmed by the U.S. Patent and Trademark Office. The isopet trademark is now registered with the World Intellectual Property Organization (WIPO) for veterinary isotopes. Countries like Australia, Canada, and the UK have 18 months to object to this registration. Dr. Korenko emphasized the significance of this development for Vivos' global branding mission in pet cancer treatment. The IsoPet® solution utilizes Yttrium-90 for targeted brachytherapy in animals and humans, indicating promising therapeutic advancements.

Vivos Inc. (OTCQB: RDGL) has enhanced its manufacturing processes for Radiogel™, crucial for FDA compliance in upcoming clinical trials. Key improvements include fifteen polymer runs and over fifty new Quality Management System documents, along with new precision process control equipment. These efforts aim to accelerate pre-clinical testing and strengthen IDE submission to the FDA, expected within 90-120 days. The company is also exploring contracts for international production of RadioGel™ and IsoPet®. CEO Korenko emphasized that these advancements make the company a serious contender in cancer treatment for both animals and humans.

Vivos Inc (RDGL) has announced its participation in the LD 500 investor conference, scheduled for September 3, 2020, at 1:40 PM PST. Dr. Mike Korenko, CEO, will present virtually, emphasizing the accessibility of this event amid COVID-19 restrictions. The conference runs from September 1 to 4, offering a platform for unique companies in the microcap space. Vivos specializes in an Yttrium-90 based injectable brachytherapy device for treating tumors in humans and animals, utilizing proprietary hydrogel technology for targeted radiation treatment.